Wed. Apr 24th, 2024

Novel immunotherapy demonstrates Long-Lasting benefits HRP Ovarian Cancer

By Owner Dec 13, 2022

A small randomized trial demonstrated that novel maintenance immunotherapy(VIGIL) provided durable disease control in homologous repair proficient (HRP) ovarian cancer.

By Owner

Related Post

Social media & sharing icons powered by UltimatelySocial

Enjoy this blog? Please spread the word :)